



Nordic Life Science Days 2014 & ECCP 2014  
Invest - Partner - Network  
7 - 9 September, Stockholm Waterfront



Produced by SwedenBIO, the Swedish Life Science Industry Organization  
in cooperation with Oslo Cancer Cluster and Toulouse Cancer-Bio-Santé Cluster

[www.nlsdays.com](http://www.nlsdays.com)


# ECCP Oncology Track Sessions

Session 1: September 8<sup>th</sup> 16:00 h – 17:30h

## Early-stage oncology opportunities – Teaming up for the success stories of tomorrow

Moderator: **Ketil Widerberg**, Managing Director Oslo Cancer Cluster

- **Dr. Corinne Venot**, Sanofi Oncology Division, Oncology Business Opportunity
- **NORTH Academic Innovation Showcase**  
Pre-commercial oncology projects from Nordic TTOs and Incubators are presented in short pitches (6 - 8 pitches, *details will be available by end of June*)
- Early phase innovation from Health Capital Berlin-Brandenburg: Alrise Biosystems GmbH and Myelo Therapeutics
- **Maria Bobadilla**, Senior Director, Academic Innovation Partnering, Hoffmann-La Roche



Nordic Life Science Days 2014 & ECCP 2014  
Invest - Partner - Network  
7 - 9 September, Stockholm Waterfront



Produced by SwedenBIO, the Swedish Life Science Industry Organization  
in cooperation with Oslo Cancer Cluster and Toulouse Cancer-Bio-Santé Cluster

[www.nlsdays.com](http://www.nlsdays.com)

Session 2: September 9th 9:00 h – 10:30

## Cancer Immunotherapies – Novel opportunities via disruptive innovation

Moderator: **Johan Christenson** MD, PhD, Partner HealthCap

- **Lubor Gaal**; Head of Europe, Strategic Transactions Group; Bristol-Myers Squibb
- **Dr Loic Vincent**, Sanofi Oncology Division, Oncology Business Opportunity
- **Dr Bertil Jonsson**, MD, Vice-Chair, CHMP Efficacy Working Party - Human Medicines & Swedish Medical Products Agency

### ***Spotlight: Innovation ecosystems in Immuno-Oncology***

The speakers will provide an overview of academic centres, spin-offs and emerging pipelines in their cluster:

- **Medicon Valley**, Sweden / Denmark: **Sybille Lenz**, CEO Alligator Bioscience
- **Oslo Cancer Cluster**, Norway: **Øyvind Arnesen**, CEO Ultimovacs AS
- **Cancer-Bio-Santé**, Toulouse, France: **Prof. Jean-Jacques Fournié**, Director Cancer Research Center of Toulouse
- **Cancer Campus** / Medicien, Paris, France; **Erwan Corcuff**, CEO Axenis
- **BioWin**, Wallonia, Belgium: **Dominique Demonté**, Director of the BIOPARK Charleroi Brussels South, Université Libre de Bruxelles



Nordic Life Science Days 2014 & ECCP 2014  
Invest - Partner - Network  
7 - 9 September, Stockholm Waterfront



Produced by SwedenBIO, the Swedish Life Science Industry Organization  
in cooperation with Oslo Cancer Cluster and Toulouse Cancer-Bio-Santé Cluster

[www.nlsdays.com](http://www.nlsdays.com)

Session 3, September 9<sup>th</sup>, 2014, 11:00 – 12:30h

## Biomarkers, Biobanks and Big Data in Oncology – How to accelerate product development and improve patient treatment?

Moderator: **Prof. Carl Borrebaeck**, CREATE Health, Lund University

### *Advancing infrastructures to exploit biobanks assets:*

- The power of coupling biobanks and national health registries: **Christian Jonasson**, CSO Lifandis AS
- Longitudinal data and samples from cancer patients – why does it have to be so hard? The U-CAN project, **Dr. Tobias Sjöblom**, Uppsala University
- SciLifeLab's cancer stem cell program; **Dr. Sven Nelander**, Department of Immunology, Genetics and Pathology, Cancer and Vascular Biology, Uppsala University (*tbc*)
- **Prof. Juni Palmgreen**, SeRC - The Swedish e-Science Research Centre; eScience for Cancer Prevention and Control

### *Industry Case Studies:*

- **Jean-Pol Detiffe**, CEO OncoDNA
- **Jean-Francois Pouliot**, Nordic Regional Medical Lead Oncology, MSD

### *Panel discussion:*

including **Maria Fagerkvist**, Vice Director of the Swedish trade association for the research-based pharmaceutical industry to wrap up industry needs as starting point for panel discussion (*tbc*) and speakers of this session

- How to exploit (Nordic) assets like Biobanks, health registries, novel tools and eScience approaches for the discovery and validation of biomarkers?
- How can existing limitations and challenges be addressed to accelerate product development and improve patient treatment?